Please see important product update news from our parent company, Telix Pharmaceuticals.______________________The U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through payment status for Gozellix® (kit for gallium-68 gozetotide injection), Telix’s next-generation PSMA-PET imaging agent for suspected metastatic or recurrent prostate cancer.Effective 1 October 2025, this designation enables separate reimbursement under the Hospital Outpatient Prospective Payment System (HOPPS).This will reduce the out-of-pocket burden for patients, enhance patient access to advanced prostate cancer imaging and simplify payment for providers. Read more on our website here: https://bit.ly/4mzaVODSelected Important Safety Information: ● There is a risk PET scan images with GOZELLIX may be misinterpreted or may be affected by other factors. ● GOZELLIX involves exposure to small amounts of radioactivity; long-term cumulative radiation exposure is associated with increased cancer risk. ● GOZELLIX is used with an Ascorbic Acid Stabilizer, which contains sodium metabisulfite, a sulfite that may cause life-threatening hypersensitivity reactions including anaphylaxis. ● The most commonly reported adverse reactions include fatigue, nausea, constipation and vomiting. These adverse reactions each typically occurred in ≤1.2% of patients in clinical trials. This is not the full important safety information. The approved uses and additional safety information is available at https://lnkd.in/gS92j7sT.